Shire Uses Foresight To Expand In Ophthalmology
This article was originally published in The Pink Sheet Daily
Executive Summary
Shire acquired Foresight Biotherapeutics for $300 million, gaining a late-stage drug for pink eye that will be a commercial complement to lifitegrast.